Objectives-The low sensitivity of ultrasonography (US) for diagnosing axillary lymph node metastasis in patients with breast cancer has led to the development of multiple tools in an attempt to increase preoperative sensitivity, including secondlook US. We compared axillary lymph node metastasis predictor scores with postsurgical findings, using the Memorial Sloan Kettering Cancer Center (MSKCC; New York, NY) and Evidencio (www.evidencio.com) nomograms: 2 freely available online predictor tools.
A n accurate tool for predicting axillary lymph node metastasis in patients with breast cancer is paramount, as it directs the treatment and prognosis. 1, 2 The methods for evaluating this condition continue to evolve over time. The sensitivity of axillary ultrasonography (US) for identifying pathologic nodes remains low, at 30% to 60%. 3 Sentinel lymph node biopsy has a false-negative rate of 10%. [4] [5] [6] Moreover, it is an invasive procedure. A noninvasive tool for identifying patients at high risk for axillary metastasis would have profound implications. In these patients with normal first axillary US findings, second-look US with biopsy may potentially identify involved nodes.
In the light of the recent American College of Surgeons Oncology Group Z0011 Trial, 7 it is even more crucial to identify the subgroup of patients with 2 or fewer nodes in whom axillary lymph node dissection can be potentially avoided after sentinel lymph node biopsy. In a similar vein, sentinel lymph node biopsy can be spared if we can accurately identify low-risk patients. 8 Additionally, earlier identification of axillary disease can lead to more candid discussions between patients and clinicians regarding treatment options.
There are various online tools that are freely available on the Worldwide Web to predict the percentage of risk of axillary nodal metastasis. A new nomogram incorporating US axillary lymph node measurement, Evidencio (www.evidencio.com; world's first online prediction model library), and a more commonly used nomogram from Memorial Sloan-Kettering Cancer Center (MSKCC; New York, NY) to assess axillary nodal status 9, 10 are freely available. The main purpose of this study was to determine whether these online tools can predict the axillary status by comparison with postoperative axillary findings. In effect, this work was an external validation study of these nomograms to predict whether the models' results are valid in a different population for clinical use. In particular, we were interested in determining whether the online score could identify patients with low-, intermediate-, or high-load nodal disease, which could potentially lead to second-look US in high-risk patients with initial normal axillary US findings.
Materials and Methods
Records of 450 patients with breast cancer treated in this tertiary referral center between January 2013 and December 2015 were evaluated. The need for ethical approval or consent was waived, as this work was a retrospective study. Patients with early-stage tumors (T1 and T2) and with complete medical information were included in the study, irrespective of their axillary status. Patients with advanced disease (T3 and T4), those with ductal carcinoma in situ, and those who received neoadjuvant chemotherapy or had incomplete medical information were excluded from this analysis. Patients were also excluded if information regarding preoperative axillary lymph nodes on US was unavailable, as variables such as lymph node cortical thickness, transverse diameter, and hilum status were essential for the calculations involved in Evidencio. After these exclusions, 194 patients were selected for the final analysis.
Several variables were recorded for this study, such as each patient's age, tumor quadrant, histologic type and size, receptor status, presence of lymphovascular invasion, nuclear grade, clinical axillary staging, sentinel lymph node biopsy results, number of lymph nodes dissected during axillary lymph node dissection, and number of nodes involved with metastasis.
Ultrasonography performed in the hospital's onestop breast clinic provided images of patients' axillary lymph nodes. These images were used to measure the perpendicular thickness of the cortex from the hilum and the diameter of the short axis of the node, in addition to assessing the presence or absence of a fatty hilum (Figure 1 ).
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The human epidermal growth factor receptor 2 (HER2) status was tested with immunohistochemical staining, and semiquantitative scoring was used. Patients with equivocal HER2 expression were further analyzed by fluorescence in situ hybridization.
Mean MSKCC and Evidencio nomogram scores were calculated for each patient, after adjustment with respect to the number of postoperative nodes as a covariate. MSKCC nomogram scores were obtained by entering data on the website nomograms.mskcc.org/ breast/for SLN (MSKCC nomogram 1). Similar values were calculated by entering data in Evidencio (www.evidencio.com) for predicting axillary metastasis in breast cancer patients. The variables used in each nomogram are outlined in Table 1 .
All patients with clinically and radiologically normal axilla underwent sentinel lymph node biopsy. Lymph nodes were diagnosed as positive if they were found to be involved with metastasis by either conventional hematoxylin-eosin or immunohistochemistry. Lymph node metastasis was divided into 3 groups based on size: macrometastasis (>2 mm), micrometastasis (0.2-2 mm) and isolated tumor cells (<0.2 mm). Patients with micrometastasis or macrometastasis in their lymph nodes underwent axillary lymph node dissection, along with standard treatment as per the local protocol. For the purpose of this study, patients were divided into 3 groups based on the postoperative (biopsy or dissection) lymph node status as follows: patients with no axillary involvement, including patients with isolated tumor cells and micrometastasis (group 0); 1 node involved with macrometastasis (group 1); and 2 or more nodes involved with macrometastasis (group 2).
For statistical analysis, the 3 groups were compared for any differences in mean nomogram scores. The age of the patient, tumor size, receptor status, presence of lymphovascular invasion, and tumor grade were also evaluated for any differences in their values among the groups. One-way analysis of variance was used for evaluating any differences in the groups when analyzing scale variables, and a v 2 square test was used for nominal variables. SPSS version 21 software (IBM Corporation, Armonk, NY) was used for data analysis, with P < .05 taken as statistically significant.
Results
Of the 194 patients, 124 were placed in group 0, 27 in group 1, and 43 in group 2. The histologic tumor types of all 194 patients were recorded. There were 144 (74.2%) patients with infiltrating ductal carcinoma, 22 (11.3%) each with lobular carcinoma and mixed tumors, 2 (1.0%) with mucinous adenocarcinoma, and 1 (0.5%) each with apocrine adenocarcinoma, invasive intraductal papillary carcinoma, micropapillary adenocarcinoma, and papillary carcinoma. Of these types of tumors, 15 (7.7 %) were histologic grade 1, 85 (43.8%) were grade 2, and 94 (48.5%) were grade 3. v 2 square tests performed between histologic grades and the 3 nodal groups showed no association between the tumor grade and axillary status (P 5 .236; Table 2 ).
The mean ages of the patients in the 3 nodal groups were also calculated. The mean ages were 66.44 (SE, 1.174) years in group 0, 62.56 (SE, 2.863) years in group 1, and 65.44 (SE, 1.986) years in group 2. One-way analysis of variance showed no significant differences in age at the time diagnosis between the various groups (P 5 0.387), indicating that axillary node involvement was not influenced by the age at diagnosis.
There were statistically significant differences in scores between the 3 nodal groups when using MSKCC (P < .001) as well as Evidencio (P < .001). In conjunction with these findings, increasing mean scores for both MSKCC and Evidencio were seen with increasing numbers of positive nodes. Figure 2) . The minimum values of the tools at which 1 or more nodes were involved were 18 and 3 for In addition to those findings, there were significant differences in postsurgical invasive tumor sizes across the nodal groups (P < .001), with greater mean sizes in groups with more positive nodes. The mean invasive tumor sizes were 26.14 (SE, 1.513) mm in group 0, Figure 2 . A, MSKCC score distribution across the 3 nodal groups. B, Evidencio score distribution across the 3 nodal groups. In the study population, 122 patients were found to be estrogen receptor (ER) positive and HER2 negative, 65.6% of whom were in group 0, 12.3% in group 1, and 22.1% in group 2. Thirty-one patients were ER negative and HER2 negative, and of these patients, 77.4% were in group 0, 12.9% in group 1, and 9.7% in group 2. No significant association was established between the ER and HER2 status and the number of positive nodes, as proven by results obtained from v 2 tests performed between groups 0, 1, and 2 with ER-positive and HER2-negative results (P 5 .683) and ER-negative and HER2-negative results (P 5 .159; Table 2 ).
The Spearman correlation coefficient between Evidencio and MSKCC was r 5 0.671 (P < .001; Figure 3 ). Lymphovascular invasion was found to be significantly associated with axillary nodal involvement (P 5 .003).
Discussion
Sentinel lymph node biopsy is an effective method for evaluating lymph nodes within axilla and is mainly used for clinically and radiologically normal axilla. However, it has a false-negative rate of up to 10%. 12 Moreover, traditional treatment demands a further second invasive procedure of axillary lymph node dissection if sentinel lymph node biopsy results are positive. Studies have shown that in 40% to 70% of patients, sentinel lymph nodes are the sole lymph nodes that are involved, making axillary lymph node dissection unnecessary in this subgroup of patients. 13, 14 Furthermore, axillary lymph node dissection carries an increased complication rate and prolongs hospitalization.
It is now appreciated that the crucial issue for patients with positive sentinel node biopsy results is not so much the probability of nonsentinel node involvement per se but rather predicting those patients who have a sufficiently low burden of disease in the nonsentinel nodes, which can be adequately dealt with by adjuvant systemic therapies (or radiation, which captures the lower axillary nodes). It would be useful if this subgroup of patients could be identified with the help of other tools, which could then potentially lead to avoidance of axillary lymph node dissection after sentinel lymph node biopsy. Similarly, high-risk patients identified with the help of the online tools with normal first axillary US findings could warrant second-look axillary US or even magnetic resonance imaging (MRI). Although to the best of our knowledge, there are no studies documenting second-look axillary US directed by nomograms, MRIdirected second-look US can lead to potential identification of involved lymph nodes, mostly by reducing the threshold of sampling of borderline axillary lymph nodes in our experience. Magnetic resonance imaging-directed second-look US has been evaluated for breast lesions in many studies. [15] [16] [17] Abe et al 17 studied 202 lesions after MRI and found second-look US to be useful in the decision-making process, especially for MRI-detected breast masses. In another study by Hieken et al, 18 the value of second-look axillary US after MRI was evaluated. In a total of 505 patients who underwent MRI, 21 had abnormal axillary findings on MRI with negative initial axillary US findings or with no preceding axillary US (33 patients). Axillary US was performed in 29 of these 54 patients, and the findings were positive in 3 (10%). Another subgroup of patients who could potentially benefit from an accurate tool are the very low-risk patients with negligible chances of axillary lymph node involvement, for whom sentinel lymph node biopsy can be avoided altogether.
In this study, both the MSKCC and Evidencio nomograms were tested for any differences in these 3 subgroups of patients: low risk, intermediate risk (1 node), and high risk (>2 nodes). Both MSKCC and Evidencio scores increased with increasing axillary involvement and showed statistically significant differences in the nomogram scores in these 3 groups of patients. MSKCC nomograms have been evaluated in many previous studies, as they were among the earliest established nomograms. 9 The area under the receiver operating characteristic curve was 0.76 for sentinel lymph nodes. 9 After that study, more than 30 studies have evaluated these nomograms for sentinel and nonsentinel lymph nodes, 19, 20 and most reported area under the curve values higher than 0.7 for the MSKCC nomogram, proving its validity. Although the Evidencio nomogram only evaluates 6 variables, 10 the MSKCC nomogram is more extensive and uses 9 patientdependent variables. 21 The Evidencio nomogram for predicting axillary node metastasis used in this study was designed by Qiu et al, 10 using 6 variables that were identified by a multivariate regression analysis to be associated with axillary lymph node metastasis: namely, lymph node cortical thickness and transverse diameter, hilum status, ER status, tumor size, and histologic grade. It is the first nomogram that incorporates information obtained from US scans. The area under the curve was 0.864, reflecting good discrimination between positive and negative nodes. 10 In this study, nomogram scores were found to be predictive of axillary involvement, but results were overlapping, making it difficult to suggest a true cutoff value. Breast cancer itself is a heterogeneous entity with many molecular subtypes. It is only now that we are beginning to understand the multiple oncogenic pathways, which can show mutations in patients with breast cancer. Results from this study underscore our limited, albeit evolving, knowledge about the heterogeneity of breast cancer. There may be other unknown variables that affect axillary involvement, which in turn affect the prediction accuracy of nomograms. For example, recent studies suggest C-erb-2 as an emerging negative prognostic factor, but our knowledge about its effect on lymph node status is limited. 22 In this study, increasing tumor size and lymphovascular invasion were associated with increasing axillary involvement. Those findings are in keeping with previous studies by Ravdin et al 23 and Gann et al. 24 Tseng et al 25 evaluated 1325 patients and found increasing tumor size, the presence of lymphovascular invasion, and an HER2-positive status with increasing axillary involvement. The authors did not find any significant difference between 2 groups with regard to age and the ER status, similar to this study. The strongest predictor of axillary metastasis in their model was lymphovascular invasion, followed by grade, tumor size, and HER2 status. That study was different with respect to this study, as there were only 2 groups of axillary involvement: axillary metastasis present or absent. Barth et al 26 found that lymphovascular invasion, grade, and tumor size were predictive of axillary nodal metastasis, with lymphovascular invasion being the strongest predictor. 25, 26 The presence of these higher risk factors can direct second-look US or MRI, and identification of pathologic lymph nodes could lead to possible avoidance of axillary surgery.
To our knowledge, this study is one of the first studies of its kind evaluating online tools based on recent American College of Surgeons' Oncology Group Z0011 trial results. 7 Our study evaluated the intermediate-risk group of axillary metastasis, similar to Z0011. Second, all histologic evaluations were uniform and maintained by in-house pathologists. Third, as far as we are aware, our study was the only study that compared 2 online nomograms to predict the probability of axillary lymph node metastasis, 1 of which uses accurate lymph node information obtained from US. The results attained in this study indicate that a greater number of positive nodes correspond to a higher score on the MSKCC and Evidencio nomograms. These nomograms also correlated with each other at a significant level: ie, a higher MSKCC score was associated with a higher Evidencio score. These results demonstrate that nomograms can provide extra information to patients regarding their condition. This better understanding of their condition presents patients with the opportunity to be involved in their care through shared decision making. However, in their current state, these scores cannot be used as sole clinical decision makers because of their overlap.
There were certain limitations of this study. First, data reproducibility in this study may be affected by interobserver variability while measuring certain variables such as the cortical thickness and transverse diameter by US. Second, this work was a retrospective study with small numbers, and a larger prospective study with larger numbers of patients' dependent variables would be helpful. Third, we also note that neither nomogram included the HER2 status, which previous studies suggest may have an impact on the prognosis. 24 Fourth, postsurgical tumor sizes were used to calculate the scores, rather than imaging sizes, because of variability in sizes between imaging modalities. However, we presumed if the scores of the nomograms with postsurgical sizes overlap, as in this study, results for various imaging sizes would be even more nondiscriminatory. Also, there would have been some dilution of scores among the 3 groups due to the inclusion of micrometastasis in the low-risk group (group 0). Last, in this study, we could not test for the relationship between the progesterone receptor status and axillary involvement because of limited data on progesterone receptors in our department.
In summary, although the above-evaluated nomograms can be useful in shared decision making by both physicians and patients, it is not possible to suggest an accurate cutoff value on which clinical decisions could be based. Further development of these nomograms by incorporating more patient-dependent variables such as genetic markers and HER2, followed by more validation studies, would be needed for the nomograms to be used confidently in clinical settings.
